Literature DB >> 31784355

Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry.

Iva Golemi1, Lauren Cote2, Omer Iftikhar3, Benjamin Brenner4, Alfonso Tafur5, Behnood Bikdeli6, Carmen Fernández-Capitán7, José María Pedrajas8, Remedios Otero9, Roberto Quintavalla10, Manuel Monreal11.   

Abstract

OBJECTIVE: Overlap exists between the risk factors for coronary artery disease and venous thromboembolism (VTE). However, a paucity of data is available on the incidence of major acute cardiovascular events (MACE) and major adverse limb events (MALE) among patients presenting with VTE. Moreover, it is unknown whether the rate of cardiovascular outcomes differs among patients with unprovoked vs provoked VTE.
METHODS: We analyzed the data from 2009 to 2017 in the Registro Informatizado de Enfermedad Tromboembólica registry, an ongoing, multicenter, international registry of consecutive patients with a diagnosis of objectively confirmed VTE. The query was restricted it to patients with data entry for the arterial outcomes. The baseline prevalence of coronary artery disease risk factors was compared between patients with provoked (ie, immobility, cancer, surgery, travel >6 hours, hormonal causes) and unprovoked VTE. After the initial VTE event, we followed up patients for the composite primary outcome of incident MACE (ie, stroke, myocardial infarction, unstable angina) and/or MALE (ie, major limb events). We used the χ2 test for baseline associations and a Cox proportional hazard for multivariate analysis. We used IBM SPSS, version 24 (IBM Corp, Armonk, NY) for statistical analysis. A P value of <.05 was considered statistically significant.
RESULTS: We analyzed the data from 41,259 patients with VTE, of whom 22,633 (55.6%) had experienced a provoked VTE. During follow-up, the patients with provoked VTE were more likely to develop MACE or MALE than were patients with unprovoked VTE (hazard ratio [HR], 1.3; 95% confidence interval [CI], 1.1-1.5). The association of arterial events with recent immobility (HR, 1.4; 95% CI, 1.5-12.1) and cancer (HR, 1.7; 95% CI, 1.4-1.9) was strong. After adjusting for multiple conventional cardiovascular risk factors, provoked VTE, compared with unprovoked VTE, was significantly associated with an increased hazard for MACE (HR, 1.4; 95% CI, 1.1-1.7). Cancer remained a significant adjusted predictor for both MACE (HR, 1.7; 95% CI, 1.4-2.1) and MALE (HR, 2.1; 95% CI 1.01-4.6) in those with provoked VTE.
CONCLUSIONS: Among patients with VTE, provoked cases, specifically those with cancer-associated VTE, have an increased risk of major arterial events.
Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Major adverse cardiovascular events; Major adverse limb events; Provoked; VTE; Venous thromboembolism

Year:  2019        PMID: 31784355     DOI: 10.1016/j.jvsv.2019.03.011

Source DB:  PubMed          Journal:  J Vasc Surg Venous Lymphat Disord


  3 in total

1.  The effect of deep vein thrombosis on major adverse limb events in diabetic patients: a nationwide retrospective cohort study.

Authors:  Po-Chang Wang; Tien-Hsing Chen; Chang-Min Chung; Mei-Yen Chen; Jung-Jung Chang; Yu-Sheng Lin; Pao-Hsien Chu; Yun-Shing Peng; Ming-Shyan Lin
Journal:  Sci Rep       Date:  2021-04-13       Impact factor: 4.379

2.  Cancer-Associated ThrOmboSIs - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - Baseline characteristics and clinical outcomes.

Authors:  Anthony Maraveyas; Jan Beyer-Westendorf; Agnes Y Lee; Lorenzo G Mantovani; Yoriko De Sanctis; Khaled Abdelgawwad; Samuel Fatoba; Miriam Bach; Alexander T Cohen
Journal:  Res Pract Thromb Haemost       Date:  2021-11-30

3.  Accelerated fibrin clot degradation is associated with arterial thromboembolism in patients following venous thrombosis: a cohort study.

Authors:  Sandra Mrozinska; Ewa Wypasek; Elżbieta Broniatowska; Anetta Undas
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.